Prevention of adverse drug events and cost savings associated with PharmD interventions in an academic Level i trauma center: An evidence-based approach

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 6, 2012, Pages 1484-1490

  Hamblin, Susan ^a   Rumbaugh, Kelli ^a   Miller, Richard ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

adverse drug events; cost savings; Pharmacy interventions; trauma service

Indexed keywords

ALPRAZOLAM; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BUPRENORPHINE PLUS NALOXONE; CARDIOVASCULAR AGENT; DAPTOMYCIN; DEXMEDETOMIDINE; DIAZEPAM; DROTRECOGIN; ENOXAPARIN; FENTANYL; GASTROINTESTINAL AGENT; HALOPERIDOL; HEPARIN; IMMUNOGLOBULIN; INSULIN; MIDAZOLAM; MORPHINE; OLANZAPINE; PROPOFOL; RITUXIMAB; SEDATIVE AGENT; THYMOCYTE ANTIBODY; UNINDEXED DRUG;

ACUTE KIDNEY FAILURE; ADVERSE DRUG REACTION; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BLEEDING; CHEMOPROPHYLAXIS; CLINICAL PHARMACY; CONFUSION; COST CONTROL; DRUG COST; DRUG QUALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EMBOLISM PREVENTION; EMERGENCY HEALTH SERVICE; EVIDENCE BASED PRACTICE CENTER; HEALTH CARE COST; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; INSULIN TREATMENT; INTENSIVE CARE UNIT; INTERNET; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; ONLINE SYSTEM; PHARMACIST; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; QT PROLONGATION; RETROSPECTIVE STUDY; SALARY; THROMBOSIS PREVENTION; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ACADEMIC MEDICAL CENTERS; COST SAVINGS; DRUG COSTS; DRUG TOXICITY; HOSPITAL COSTS; HUMANS; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; RETROSPECTIVE STUDIES; TENNESSEE; TRAUMA CENTERS;

EID: 84871256158     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e318267cd80     Document Type: Article

References (29)

1. Society of Critical Care Medicine and American College of Clinical Pharmacy. Position paper on critical care pharmacy services. Pharmacotherapy. 2000;20:1400-1406.
2. Erstad BL, et al. Interdisciplinary patient care in the intensive care unit: focus on the pharmacist. Pharmacotherapy. 2011;31:128-137.
3. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003;29:691-698.
4. Cullen DJ, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997;25:1289-1297.
5. Kane-Gill SL, Jacobi J, Rothschild JM. Adverse drug events in intensive care units: risk factors, impact, and the role of team care. Crit Care Med. 2010;38(Suppl 6):S83-S89.
6. Powell MF, Solomon DK, McEachen RA. Twenty-four hour emergency pharmaceutical services. Am J Health Syst Pharm. 1985;42:831-835.
7. Fairbanks RJ, et al. Clinical pharmacy services in an emergency department. Am J Health Syst Pharm. 2004;61:934-937.
8. Kasuya A, et al. Clinical pharmacy on-call program in the emergency department. Am J Emerg Med. 1986;4:464-467.
9. Patanwala AE, Hays DP. Pharmacist's activities on a trauma response team in the emergency department. Am J Health Syst Pharm. 2010;67: 1536-1538.
10. Bates DW, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997;277:307-311.
11. Suh DC, et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34:1373-1379.
12. Classen DC, et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997;277: 301-306.
13. Bergstrom RJ, McLaughlin EJ. Financial planning for the risk of long life; how to cope with the rising cost of getting old. J Accountancy. 1991; 172:50-55.
14. Consumer Healthcare Products Association. Newsletter 2005.Available at: http://www.chpa-info.org/web/press-room/statistics/healthcare-inflation. aspx. Accessed August 25, 2005
15. Hewitt Associates. Hewitt Health Value Initiative. 2005. Available at: http://was4.hewitt.com/hewitt/resource/newsroom/pressrel/2005/10-10-05.htm. Accessed October 18, 2005.
16. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200-1205.
17. Eisenberg JM, et al. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med. 1987;107:900-909.
18. Slaughter RL, Cappelletty DM. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring. Pharmacoeconomics. 1998;14:385-394.
19. Hitt CM, et al. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy. 1997;17:810-814.
20. Streetman DS, et al. Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy. 2001;21:443-451.
21. Devlin JW, Tyburski JG, Moed B. Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma. Pharmacotherapy. 2001;21:740-747.
22. Brophy GM, et al. Pharmacist impact on posttraumatic seizure prophylaxis in patients with head injury. Pharmacotherapy. 2002;22:251-255.
23. Taheri PA, et al. Trauma service cost: the real story. Ann Surg. 1998; 227:720-724; discussion 724-725.
24. Kopp BJ, et al. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64:2483-2487.
25. Camire E, Moyen E, Stelfox HT. Medication errors in critical care: risk factors, prevention and disclosure. CMAJ. 2009;180:936-943.
26. Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med. 2003;348:2526-2534.
27. Darko W, et al. Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy. 2003;23:643-650.
28. Horn E, Jacobi J. The critical care clinical pharmacist: evolution of an essential team member. Crit Care Med. 2006;34(Suppl 3):S46-S51.
29. Fox BI, et al. Selecting a clinical intervention documentation system for an academic setting. Am J Pharm Educ. 2011;75:37.